Michael Orozco
Optometrist · San Antonio, TXNPI 1568467298
Payments from drug & device makers
Across 292 payments — averaging $37.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$3K
- Bausch & Lomb Americas Inc.$1K
- Sight Sciences, Inc.$1K
- Novartis$844
- Oyster Point Pharma, Inc.$809
- AbbVie$772
- plus $4K from 18 others
What the payments were for
- Food & beverage$10,970100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 38 | $2,721 |
| Bausch & Lomb Americas Inc. | 32 | $1,218 |
| Sight Sciences, Inc. | 14 | $1,103 |
| Novartis | 39 | $844 |
| Oyster Point Pharma, Inc. | 33 | $809 |
| AbbVie(2 entities) | 26 | $772 |
| Sun Pharmaceutical Industries Inc. | 27 | $624 |
| Dompe US, Inc. | 20 | $590 |
| Alcon | 14 | $523 |
| Tearlab Corp | 6 | $450 |
| Harrow Eye, LLC | 9 | $394 |
| Kala Pharmaceuticals, Inc. | 12 | $239 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $147 |
| Aerie Pharmaceuticals, Inc. | 2 | $129 |
| Optovue, Inc. | 1 | $87 |
| Amgen | 4 | $83 |
| Shire North American Group Inc | 3 | $51 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $49 |
| Thea Pharma Inc. | 3 | $49 |
| Tarsus Pharmaceuticals, Inc. | 1 | $25 |
| Optos, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| Santen Inc. | 1 | $13 |
| Coopervision Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$677
- AmnioGraft$677
- XIIDRA$477
- TEARCARE SYSTEM$424
- TearCare SmartLid$412
- TEARCARE(TM) (2.2) SYSTEM KIT$412
- TYRVAYA$355
- TearLab Osmolarity System$295
- VEVYE$269
- MIEBO$250
- Oxervate$247
- Rhopressa$125
- Rocklatan$125
- DURYSTA$125
- EYSUVIS$125
- VYZULTA$125
- TRYPTYR$125
- OZURDEX$117
- LIPIFLOW SYSTEM ACTIVATOR II (DISPOSABLE$114
- ScoutPro Osmolarity System$108
How this compares
$10,970 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $675,827 |
| XiidraLifitegrast | 158 | $218,662 |
| RestasisCyclosporine | 113 | $137,504 |
| XdemvyLotilaner | 49 | $91,859 |
| Cyclosporine | 125 | $84,282 |
| MieboPerfluorohexyloctane/Pf | 65 | $56,062 |
| Bromfenac Sodium | 165 | $52,939 |
| Loteprednol Etabonate | 201 | $46,608 |
| TyrvayaVarenicline Tartrate | 34 | $21,713 |
| LumiganBimatoprost | 25 | $13,759 |
| CequaCyclosporine | 12 | $13,481 |
| AlrexLoteprednol Etabonate | 21 | $12,017 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 204 | $9,184 |
| Travoprost | 25 | $6,327 |
| EysuvisLoteprednol Etabonate | 12 | $5,771 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $590 | $675,82712 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,218 | $274,724223 claims |
| AbbVieRestasis, Lumigan | $772 | $151,263138 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $25 | $91,85949 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Alrex | $49 | $58,625222 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $809 | $21,71334 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $624 | $13,48112 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $239 | $5,77112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in San Antonio
- Mina VanrachackSan Antonio$553K
- Dawn RakichSan Antonio$113K
- Carolyn MajcherSan Antonio$86K
- Jeannine CamachoSan Antonio$83K
- Chandler MannSan Antonio$71K
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.